Dear Reader,
Welcome to the final issue of Drugs in R&D for 2021.
Anzeige
I wish to reflect on this year’s achievements, and to thank all those who have contributed their time and effort to guarantee the quality of the content published in the journal.
In 2021, over 30 articles have been published. The high quality of content published in Drugs in R&D has been reflected in the most recent impact factor of 2.594 and CiteScore™ of 5.1.
The COVID-19 pandemic has continued to present many challenges and I would like to thank all who have contributed to ensuring the journal has thrived despite the ongoing issues.
I would like to start by thanking the authors of the articles published in Drugs in R&D over the course of 2021. The enthusiasm of all authors for their chosen fields and their willingness to contribute content to the journal are crucial for its continued success.
Anzeige
The quality of published articles is also testament to the diligence of the peer reviewers. I would like to acknowledge the following individuals who acted as reviewers for Drugs in R&D in the last 12 months:
Richat Abbas, USA
Mohamed Ali, Egypt
Luis Alou, Spain
Mehmet M. Altintas, USA
Cristiano Amarelli, Italy
Sarah Anderson, USA
Jane P.F. Bai, USA
Anzeige
Gustavo Baldassarre, Italy
Paul Bastard, France
Stefania Bellino, Italy
Ragna Berthelsen, Denmark
Anzeige
Ramesh Bionpally, USA
Emanuele Bizzi, Italy
Serhat Bor, Turkey
Steven Brenner, USA
Anzeige
Ali Canbay, Germany
Enrique Carrazana, USA
Chiranjib Chakraborty, India
Phyllis Chan, USA
Sarika Chaudhary, India
Nevio Cimolai, Canada
Timothy Clinton, USA
Hugo L. Corrêa, Brazil
Dorota Danielak, Poland
Alessandro Di Filippo, Italy
Min Dong, USA
Ramón Eizaga Rebollar, Spain
Sandro Feriozzi, Italy
Michael Fettiplace, USA
Chris M. Florkowski, New Zealand
James Galloway, UK
Colin Geddes, UK
Johanna Gehin, Norway
Navin Goyal, USA
Andreas H. Groll, Germany
Sebastian Harder, Germany
Kazuhiko Hashimoto, Japan
Nadine Herrmann, Germany
Paul R. Hutson, USA
Florenzo Iannone, Italy
Berengere Koehl, France
Antonios Kolocouris, Greece
Magdalena Krajewska, Poland
Yi-Yang Lau, USA
Maxime Léger, France
David Mantle, UK
Maximilian Marhold, Austria
Ron H.J. Mathijssen, The Netherlands
Giuseppe Micali, Italy
Takashi Nakayama, Japan
Luigi Naldi, Italy
Peter Nordbeck, Germany
Aditya Padhi, Japan
Jignesh P. Patel, UK
Antoine Petitcollin, France
Nunzia Prencipe, Italy
Paul Reynolds, USA
Giovanni Rolla, Italy
Jungsu Ryu, USA
Ayad Sabry, USA
Yosuke Saka, Japan
Shigetoshi Sano, Japan
Luis Sargento, Portugal
Mitsuhito Sasaki, Japan
Regina Scherließ, Germany
Ulrich Strassen, Germany
Julie J.D. Suman, USA
Navin Suthahar, The Netherlands
Omer Toprak, Turkey
Malgorzata Trocha, Poland
Periklis Tsiros, Greece
Geoffrey T. Tucker, UK
Gian Van Vo, Vietnam
Hiroki Wakabayashi, Japan
Karin Weissenborn, Germany
Rene Westhovens, Belgium
Tony Whitehouse, UK
Uwe Wollina, Germany
Eugene E. Wright Jr, USA
Chun-Yi Wu, USA
Kanatani Yashuhiro, Japan
Masahiro Yasunaga, Japan
Jana Zdarova Karasova, Czech Republic
Enrico Zelin, Italy
Vincent Zimmer, Germany
Peying Zuo, USA
I am also very grateful to the members of the journal’s Honorary Editorial Board, who have acted as peer reviewers and authors, and have provided guidance on journal content, policy and processes.
Springer Nature has continued to support the global response to COVID-19 by making all relevant content immediately and freely available. Indeed, Drugs in R&D has published a number of papers relevant to the COVID-19 pandemic that are free to access, including:
-
Tegenge, M.A., Mahmood, I., Struble, E. et al. Dosing Considerations for Antibodies Against COVID-19. Drugs R D 21, 1–8 (2021). https://doi.org/10.1007/s40268-020-00330-3
-
Marra, F., Smolders, E.J., El-Sherif, O. et al. Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment. Drugs R D 21, 9–27 (2021). https://doi.org/10.1007/s40268-020-00333-0
-
Butterworth, R.F. Potential for the Repurposing of Adamantane Antivirals for COVID-19. Drugs R D 21, 267–272 (2021). https://doi.org/10.1007/s40268-021-00351-6
-
Rajpoot, S., Ohishi, T., Kumar, A. et al. A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor. Drugs R D 21, 273–283 (2021). https://doi.org/10.1007/s40268-021-00357-0
-
Speeckaert, R., Lambert, J., Puig, L. et al. Vaccinations in Patients Receiving Systemic Drugs for Skin Disorders: What Can We Learn for SARS-Cov-2 Vaccination Strategies?. Drugs R D 21, 341–350 (2021). https://doi.org/10.1007/s40268-021-00349-0
-
Sprute, R., Schumacher, S., Pauls, M. et al. Delayed Cutaneous Hypersensitivity Reaction to Vaxzevria (ChAdOx1-S) Vaccine against SARS-CoV-2. Drugs R D (2021). https://doi.org/10.1007/s40268-021-00358-z
The editorial program for 2022 is well under way, and I am looking forward to bringing you many high-quality and authoritative articles in the field of pharmacology over the coming year.
I thank you for your continued support.
With best wishes,
Anton van Rensburg
Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.